Eterna Therapeutics
ERNA
#10112
Rank
ยฃ7.47 M
Marketcap
ยฃ0.14
Share price
3.88%
Change (1 day)
-92.14%
Change (1 year)

P/E ratio for Eterna Therapeutics (ERNA)

P/E ratio as of April 2025 (TTM): -0.0321

According to Eterna Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0320922. At the end of 2021 the company had a P/E ratio of -1.50.

P/E ratio history for Eterna Therapeutics from 2021 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2021-1.50

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
6.64-20,777.11%๐Ÿ‡บ๐Ÿ‡ธ USA
-4.38 13,555.50%๐Ÿ‡บ๐Ÿ‡ธ USA
12.7-39,658.83%๐Ÿ‡บ๐Ÿ‡ธ USA
17.2-53,675.64%๐Ÿ‡ซ๐Ÿ‡ท France
36.9-115,055.35%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡ฆ๐Ÿ‡บ Australia
-7.63 23,675.25%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.